down arrow

Brainstorm Cell Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US10501E2019
USD
0.61
-0.02 (-3.33%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.600.63

52 Week

0.522.50
Valuation
Technical
Day's Volume

CASH

7.93 k

Shareholding (Mar 2025)

FII

0.36%

Held by 10 FIIs

DII

96.97%

Held by 3 DIIs

Promoter

0.00%

How big is Brainstorm Cell Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Brainstorm Cell Therapeutics, Inc. has a market capitalization of 9.48 million, with net sales of 0.00 million and a net profit of -11.08 million over the last four quarters. The company's shareholder's funds are -7.76 million, and total assets are 1.83 million.

Market Cap: As of Jun 18, Brainstorm Cell Therapeutics, Inc. has a market capitalization of 9.48 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -11.08 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -7.76 million, while total assets were reported at 1.83 million.

Read More

What does Brainstorm Cell Therapeutics, Inc. do?

22-Jun-2025

Brainstorm Cell Therapeutics, Inc. is a biotechnology company focused on developing adult stem cell therapies for neurodegenerative disorders like ALS, MS, and Parkinson's disease. It has a market cap of $9.48 million and reported a net profit loss of $3 million as of March 2025.

Overview: <BR>Brainstorm Cell Therapeutics, Inc. is a biotechnology company engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's disease (PD), among others, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 9.48 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 155.00% <BR>Price to Book: -1.27<BR><BR>Contact Details: <BR>Address: 1325 Avenue of the Americas Fl 28, NEW YORK NY: 10019-6583 <BR>Tel: 1 201 4880460 <BR>Fax: 1 302 6555049 <BR>Website: http://www.brainstorm-cell.com/

Read More

Who are in the management team of Brainstorm Cell Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Brainstorm Cell Therapeutics, Inc. includes Prof. Jacob Frenkel (Chairman), Dr. Irit Arbel (Vice Chairman), Mr. Uri Yablonka (Executive VP, Chief Business Officer), and several independent directors. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Brainstorm Cell Therapeutics, Inc. includes the following members:<BR><BR>- Prof. Jacob Frenkel, Chairman of the Board<BR>- Dr. Irit Arbel, Vice Chairman of the Board<BR>- Mr. Uri Yablonka, Executive Vice President, Chief Business Officer, Director<BR>- Mr. Sankesh Abbhi, Director<BR>- Dr. June Almenoff, Independent Director<BR>- Dr. Anthony Polverino, Independent Director<BR>- Mr. Malcolm Taub, Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Read More

Is Brainstorm Cell Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Brainstorm Cell Therapeutics, Inc. is in a bearish trend with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mildly bullish MACD signals on longer time frames.

As of 10 September 2025, the technical trend for Brainstorm Cell Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include bearish signals from the daily moving averages, Bollinger Bands, and KST, along with a mildly bearish reading from the Dow Theory on a weekly basis. The MACD shows mildly bullish signals on both weekly and monthly time frames, but this is overshadowed by the overall bearish trend. There is no return data available for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.06

stock-summary
Return on Equity

190.82%

stock-summary
Price to Book

-1.20

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.91%
0%
-20.91%
6 Months
-43.61%
0%
-43.61%
1 Year
-64.8%
0%
-64.8%
2 Years
-84.38%
0%
-84.38%
3 Years
-97.55%
0%
-97.55%
4 Years
-98.78%
0%
-98.78%
5 Years
-99.26%
0%
-99.26%

Brainstorm Cell Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Brainstorm Cell Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Brainstorm Cell Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include bearish signals from the daily moving averages, Bollinger Bands, and KST, along with a mildly bearish reading from the Dow Theory on a weekly basis. The MACD shows mildly bullish signals on both weekly and monthly time frames, but this is overshadowed by the overall bearish trend. There is no return data available for comparison with the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
9.70%
EBIT to Interest (avg)
-15.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
22.74%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.30
EV to EBIT
-0.79
EV to EBITDA
-0.80
EV to Capital Employed
-1.30
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (2.67%)

Foreign Institutions

Held by 10 Foreign Institutions (0.36%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -16.00% vs 52.83% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.50",
          "val2": "-2.90",
          "chgp": "13.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.90",
          "val2": "-2.50",
          "chgp": "-16.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.56% vs 29.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.50",
          "val2": "-21.20",
          "chgp": "45.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "4.70",
          "chgp": "-97.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.60",
          "val2": "-17.20",
          "chgp": "32.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.50
-2.90
13.79%
Interest
0.30
0.00
Exceptional Items
0.00
0.40
-100.00%
Consolidate Net Profit
-2.90
-2.50
-16.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -16.00% vs 52.83% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.50
-21.20
45.75%
Interest
0.10
0.00
Exceptional Items
0.10
4.70
-97.87%
Consolidate Net Profit
-11.60
-17.20
32.56%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 32.56% vs 29.22% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Brainstorm Cell Therapeutics, Inc. stock-summary
stock-summary
Brainstorm Cell Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Company Coordinates stock-summary
Company Details
1325 Avenue of the Americas Fl 28 , NEW YORK NY : 10019-6583
stock-summary
Tel: 1 201 4880460
stock-summary
http://www.brainstorm-cell.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."